

REMARKS

Claims 9, 11, 13, 15, 17, 19, 21, and 22 are pending in the present application. Claims 11, 17 and 21 are amended to delete the term "low-positive" cancer cells. No new matter is inserted into the application. Entry of the instant Supplemental Reply is respectfully requested.

Attached hereto is a marked up version showing the changes made to the application by this Amendment.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Kristi L. Rupert, Ph.D. (Reg. No. 45,702), at the telephone number of the undersigned, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART⁷, KOLASCH & BIRCH, LLP

By _____

ADM
Andrew D. Meikle, #32,868

ADM
ADM/KLR/jeb
3813-0101P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

VERSION WITH MARKINGS SHOWING CHANGES MADE

IN THE CLAIMS:

The following claims are amended:

11. (Twice Amended) The method according to claim 9, wherein said cancer cells are stimulated by class-I negative [or low-positive] cancer cells or by a class-I negative cancer cell line transduced with a cancer antigen.

17. (Twice Amended) The composition according to claim 15, wherein said lymphocytes are stimulated by class-I negative [or low-positive] cancer cells or by a class-I negative cancer cell line transduced with a cancer antigen.

21. (Amended) The method according to any one of claims 15, 17, or 19, wherein cancer antigen specific killer T cells are induced by stimulation of said lymphocytes with said class-I negative [or low-positive] cancer cells or by class-I negative cancer cell line transduced with a cancer antigen.